Law360, New York (May 25, 2004, 12:00 AM ET) -- Patient advocates and industry officials clashed at a meeting at the National Institutes of Health Tuesday to debate whether the U.S. government should issue compulsory license for an AIDS drug produced by Abbott Laboratories.
In December, Abbott Labs raised the wholesale price for a month's worth of the protease inhibitor Norvir, widely used in small doses to boost the potency of some AIDS combination-drug therapies, to $265 from $54.
The move caused an avalanche of protests from AIDS activists, who demanded a public meeting to consider...
NIH Hears Arguments Over Compulsory License For AIDS Drug
To view the full article, take a free trial now.
